ABSTRACT
The Pharmaceutical Regulatory Science Team (PRST) founded in 2005, carries out research into strategies to address the challenges and opportunities of implementing Science and Risk based decision making and manufacturing approaches. Since its inception, the PRST has continued to progress research on quality risk management (QRM), knowledge management (KM) operational excellence (OpEx), post-approval change management (PAC, and PAC 1VQ), quality metrics and related topics covered by ICH Quality Guidelines.
Recently the focus of the PRST has been on Risk Based Decision Making (RBDM) and as such has written series of 4 papers on strategies to improve RBDM effectiveness. This, the third of these papers, and it explores formality in decision making within the QRM process